Description
COMPOSITION:
Each LuciPral capsule contains: Pralsetinib ……………………… 100mg
INDICATION:
LuciPral is a kinase inhibitor indicated for treatment of
1. adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).
2. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy 1
3, Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory
DOSAGE AND USE:
The recommended dosage in adults and pediatric patients 12 years and older is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking LuciPral).
Capsule should be swallowed whole & not chewed or crushed.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of the reach of Children. Do not administered LuciLorla in Pregnancy and Lactation patient treatment.
Reviews
There are no reviews yet.